Testblu Diagnostics utilizes liquid biopsy technology to analyze cell-free DNA in dogs' blood samples, enabling the early detection of cancer before clinical symptoms arise. This proactive approach allows for timely intervention, improving treatment outcomes and reducing the financial burden associated with late-stage cancer care.
Funding
$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer is a leading cause of death in adult dogs, often detected only after clinical symptoms appear, potentially limiting treatment options and increasing healthcare costs. Traditional screening methods may not detect cancer in its early stages when treatment is most effective.
Solution
Testblu Diagnostics offers a liquid biopsy test that analyzes cell-free DNA (cfDNA) in a dog's blood to detect cancer-associated genomic changes before clinical signs are evident. This non-invasive approach allows for earlier intervention, potentially improving treatment outcomes and quality of life for the dog. The test identifies tumor-associated mutations, providing vets and owners with information to make informed decisions about the dog's health. Testblu's screening and monitoring tests are developed by vets and bioinformaticians, providing a convenient way for early detection of cancer in dogs.
Target Audience
The primary customers are veterinarians looking to offer early cancer screening to their canine patients, and dog owners, particularly those with older dogs or breeds predisposed to cancer, who want to proactively monitor their pet's health.
Features
- Liquid biopsy analysis of cell-free DNA (cfDNA) from a simple blood sample
- Detection of tumor-associated genomic alterations
- Designed for dogs 7 years and older, or 5-6 years for predisposed breeds
- Results delivered to the vet within 1-2 weeks
- Monitoring tests available to track cancer progression or recurrence